Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MSD-104
- Development stage
- Unknown
- Lead developer
- Mindstate Design Labs
- Modality
- Small Molecules
01
Overview
MSD-104 is an early-stage clinical candidate being developed by Mindstate Design Labs. It is designed as a small molecule primer-probe fixed-dose combination using the company's proprietary Osmanthus platform, which maps molecular structure and polypharmacology to high-dimensional drug-effect readouts to design specific psychoactive states. MSD-104 is currently in Phase 1b/2a clinical development; however, its specific molecular targets, active ingredients, and therapeutic indications remain undisclosed.
Beyond the preview
Go deeper on MSD-104.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MSD-104.